NSCLC patients were also analyzed for the immunosuppressive counterpart evaluating the percentage of circulating Tregs (total, active, resting, and non-suppressive) and MDSCs (PMN(Lox1+)- and M-MDSCs) before and during therapy (Figure 4). This evidence concerns the gene OLR1 and non-small cell lung carcinoma.